Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
SRPT
SRPT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SRPT News
FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks
1d ago
Benzinga
uniQure Shares Surge Following FDA Official's Departure
1d ago
Benzinga
FDA Vaccine Chief Vinay Prasad to Depart Agency
3d ago
stocktwits
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
4d ago
CNBC
FDA Faces Criticism Amid Innovation Challenges
6d ago
CNBC
Sarepta Launches Duchenne Scholarship Program for 2026-2027
Feb 27 2026
Newsfilter
Sarepta Therapeutics Invites Applications for the 9th Annual Route 79 Duchenne Scholarship Program
Feb 27 2026
moomoo
Sarepta Therapeutics Stock Falls 9% Following Larger-than-Expected Q4 Loss
Feb 26 2026
moomoo
Sarepta Therapeutics Reports Earnings Miss and Management Transition
Feb 26 2026
Benzinga
Wall Street Opens Cautiously Amid China Market Concerns
Feb 26 2026
stocktwits
Sarepta CEO Douglas Ingram to Retire by 2026 Amid Family Health Issues
Feb 26 2026
seekingalpha
Sarepta Q4 Revenue Beats Estimates but Reports Significant Loss
Feb 26 2026
stocktwits
Sarepta Therapeutics Q4 2025 Earnings Call Insights
Feb 26 2026
seekingalpha
Japan Launches ELEVIDYS Gene Therapy for DMD
Feb 24 2026
Newsfilter
Sarepta Therapeutics Inc: Chugai Pharmaceutical Co., Ltd. to Launch Elevidys Commercially in Japan
Feb 24 2026
moomoo
Sarepta Therapeutics Inc. Announces Availability of Elevidys for Duchenne Patients Aged 3 to 8 in Japan
Feb 24 2026
moomoo
Show More News
